Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹16,903 Cr
Revenue (TTM)
₹3,720 Cr
Net Profit (TTM)
₹352 Cr
ROE
11.2 %
ROCE
15.4 %
P/E Ratio
48
P/B Ratio
3.6
Industry P/E
48.01
EV/EBITDA
16
Div. Yield
0.3 %
Debt to Equity
0
Book Value
₹117.9
EPS
₹9.7
Face value
10
Shares outstanding
402,939,420
CFO
₹6,774.90 Cr
EBITDA
₹6,677.20 Cr
Net Profit
₹3,848.50 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syngene Intl
| -35.5 | -3.0 | -35.1 | -37.8 | -10.1 | -4.5 | 7.9 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Syngene Intl
| -26.0 | 21.0 | 19.8 | -5.5 | -2.0 | 98.4 | 14.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syngene Intl
|
419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 767.9 | 12,649.5 | 1,284.3 | 134.4 | -- | 30.7 | 94.1 | 10.4 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
1 min read•By Research Desk
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services,... such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited. Read more
Incorporated
1993
Chairman
Kiran Mazumdar-Shaw
Managing Director
Peter Bains
Headquarters
Bengaluru, Karnataka
Website
Looking for more details about Syngene International Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Syngene International Ltd is ₹419.85 (NSE) and ₹419.50 (BSE) as of 18-Mar-2026 IST. Syngene International Ltd has given a return of -10.12% in the last 3 years.
The P/E ratio of Syngene International Ltd is 48.01 times as on 18-Mar-2026, a 0 premium to its peers’ median range of 48.01 times.
The P/B ratio of Syngene International Ltd is 3.56 times as on 18-Mar-2026, a 16 premium to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
58.90
|
6.29
|
|
2024
|
55.31
|
6.73
|
|
2023
|
51.39
|
6.72
|
|
2022
|
60.44
|
7.45
|
|
2021
|
53.68
|
7.92
|
The 52-week high and low of Syngene International Ltd are Rs 760.00 and Rs 387.05 as of 19-Mar-2026.
Syngene International Ltd has a market capitalisation of ₹ 16,903 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Syngene International Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹8.80
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.